Natera, Inc. (NASDAQ:NTRA) Shares Acquired by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC increased its position in Natera, Inc. (NASDAQ:NTRA) by 372.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 331 shares of the medical research company’s stock after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC’s holdings in Natera were worth $52,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its holdings in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares during the last quarter. Principal Securities Inc. lifted its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after acquiring an additional 332 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its holdings in Natera by 55.0% in the fourth quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company’s stock worth $69,000 after acquiring an additional 154 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 6,702 shares of Natera stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $146.03, for a total value of $978,693.06. Following the transaction, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,695,784.62. The trade was a 3.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 669 shares of Natera stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares in the company, valued at approximately $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 307,466 shares of company stock worth $49,047,655. 7.60% of the stock is owned by insiders.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $150.87 on Thursday. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The stock has a market cap of $20.40 billion, a price-to-earnings ratio of -85.72 and a beta of 1.80. The stock’s 50 day moving average price is $162.25 and its 200 day moving average price is $149.27. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on NTRA shares. Morgan Stanley raised their target price on shares of Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. BTIG Research reissued a “buy” rating on shares of Natera in a report on Friday, February 28th. Guggenheim raised their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Finally, Barclays started coverage on Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.